Regeneron wins Eylea patent case against biosimilar developer Mylannews2023-12-28T15:03:22+00:00December 28th, 2023|Endpoints News|
IRA likely to lead to higher drug list prices and bigger rebates, Congressional Budget Office predictsnews2023-12-27T17:15:28+00:00December 27th, 2023|Endpoints News|
Cytokinetics’ genetic heart disorder drug aficamten succeeds in PhIII with ‘clean’ datanews2023-12-27T16:53:43+00:00December 27th, 2023|Endpoints News|
Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&Jnews2023-12-27T15:34:01+00:00December 27th, 2023|Endpoints News|
Iovance’s registrational lung cancer trial on hold after patient deathnews2023-12-27T14:50:53+00:00December 27th, 2023|Endpoints News|
FDA declines to grant Amgen’s Lumakras full approval in lung cancer after negative advisory committee votenews2023-12-26T16:58:59+00:00December 26th, 2023|Endpoints News|
FDA adds warning on secondary cancers for Carvykti, following agency’s inquiry into CAR-T safetynews2023-12-26T16:52:48+00:00December 26th, 2023|Endpoints News|
AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China tiesnews2023-12-26T16:31:54+00:00December 26th, 2023|Endpoints News|
J&J licenses LegoChem’s Trop2 ADC for $100M upfrontnews2023-12-26T16:24:07+00:00December 26th, 2023|Endpoints News|
Bristol Myers to buy RayzeBio for $4.1B as pharma piles into burgeoning radiopharma fieldnews2023-12-26T15:52:41+00:00December 26th, 2023|Endpoints News|
